Atypical hemolytic uremic syndrome in adults. Case report and literature review

Sonia C. Mastrapasqua Servicio de Nefrología, Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén
Oscar A. Escobar Servicio de Nefrología, Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén
María C. Martínez Servicio de Nefrología, Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén
Héctor M. Melideo Servicio de Nefrología, Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén
Maximiliano H. Ramírez Servicio de Nefrología, Hospital Provincial Neuquén Dr. Eduardo Castro Rendón, Neuquén

Keywords: hemolytic uremic syndrome, thrombotic microangiopathy, eculizumab, adults

References

Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.

Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-59.

Nester CM, Barbour T, De Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, et al. Atypical aHUS: State of the art. Mol Immunol. 2015;67(1):31-42.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-62.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, et al. Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso. Nefrologia. 2015;35(5):421-47.

Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-87.

Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost. 2014;40(4):444-64.

Nürnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542-4.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-81.

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061-73.

Taylor CM, Machin S, Wigmore SJ, Goodship TH; working Party from the Renal Association, British Committee for Standards in Haematology and the British Transplantation Society. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010;148(1):37-47.

Published

2016-09-01

How to Cite

Mastrapasqua SC, Escobar OA, Martínez MC, Melideo HM, Ramírez MH. Atypical hemolytic uremic syndrome in adults. Case report and literature review. Rev Nefrol Dial Traspl. [Internet]. 2016Sep.1 [cited 2024Nov.23];36(3):174-8. Available from: http://revistarenal.org.ar/index.php/rndt/article/view/74